PROF
Profound Medical Corp.
NASDAQ · Healthcare · Medical - Devices · CA
$6.89
+1.32%Year over year
Reported trailing growth
- Revenue
- +35.9%
- EBITDA
- +31.8%
- EBIT
- +63.0%
- EPS
- +31.7%
- Free cash flow
- -5.4%
- Operating cash flow
- -4.9%
Forward estimates
Based on analyst estimates
- Revenue
- +78.2%
- EBITDA
- +15.3%
- EPS
- +20.4%
Three-year CAGR
- Revenue
- +34.8%
- EBITDA
- -61.8%
- EBIT
- -33.4%
- Net income
- -63.6%
- EPS
- -33.6%
- Free cash flow
- -66.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026